Trends in antiarrhythmic drug use after marketing authorization of dronedarone: Comparison between Emilia Romagna (Italy) and Sweden

European Journal of Clinical Pharmacology

Volumn 69, Issue 3, 2013, Pages 715-720

  Piccinni, Carlo ^a   Raschi, Emanuel ^a   Poluzzi, Elisabetta ^a   Puccini, Aurora ^b   Cars, Thomas ^c   Wettermark, Björn ^c,d   Diemberger, Igor ^e   Boriani, Giuseppe ^e   De Ponti, Fabrizio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Drug Policy Service   (Italy)

^c STOCKHOLM COUNTY COUNCIL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antiarrhythmics; Dronedarone; Drug utilization; Interrupted time series analysis; Prescription

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DISOPYRAMIDE; DRONEDARONE; FLECAINIDE; PROPAFENONE;

ARTICLE; COMPARATIVE STUDY; DRUG MARKETING; DRUG SAFETY; DRUG USE; DRUG UTILIZATION; HUMAN; ITALY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; SWEDEN; TIME SERIES ANALYSIS; TREND STUDY;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; DRUG PRESCRIPTIONS; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HEALTHCARE DISPARITIES; HUMANS; ITALY; MARKETING OF HEALTH SERVICES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; SWEDEN; TIME FACTORS;

EID: 84877154061     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1377-4     Document Type: Article

References (22)

1. Lip GY, Tse HF, Lane DA (2012) Atrial fibrillation. Lancet 379:648-661
2. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ (2009) Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 360:668-678
3. Gillis AM, Skanes AC (2011) Comparing the 2010 North American and European atrial fibrillation guidelines. Can J Cardiol 27:7-13
4. National Institute for Health and Clinical Excellence (NICE) (2010) Dronedarone for the treatment of nonpermanent atrial fibrillation. http://www.nice.org.uk/nicemedia/live/13115/50469/50469.pdf. Accessed 9 February 2012
5. Emilia Romagna Region Health Authority (2010) Scheda di valutazione del farmaco Dronedarone e Piano terapeutico regionale. http://www.saluter.it/ documentazione/ptr/elaborati/114-dronedarone-rev/view. Accessed 9 February 2012
6. U.S.Food and Drug Administration (2011) Severe liver injury associated with the use of dronedarone (marketed as Multaq). http://www.fda.gov/drugs/ drugsafety/ucm240011.htm. Accessed 23 January 2012
7. European Medicines Agency (2011) Questions and answers on the possible risk of liver injury with Multaq (dronedarone). http://www.ema.europa.eu/docs/ en-GB/document-library/Medicine-QA/human/001043/WC500101075.pdf. Accessed 23 January 2012
8. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum A, Blomstrom P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacretaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbuchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsanyi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH (2011) Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 365:2268-2276
9. European Medicines Agency (2011) Benefit-risk review of Multaq started. http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2011/09/ WC500112800.pdf. Accessed 2 February 2012
10. U.S.Food and Drug Administration (2011) FDA Drug Safety Communication: Review update of Multaq (dronedarone) and increased risk of death and serious cardiovascular adverse events. http://www.fda.gov/Drugs/DrugSafety/ucm283933. htm. Accessed 2 February 2012
11. Capucci A, Guerra F, Antenucci C, Antonicelli R, Bocconcelli P, Boriani G, Busacca P, Ciampani N, Della CS, Gabrielli D, Galvani M, Margheri M, Melandri F, Modena MG, Perna GP, Pieri P, Piovaccari G, Pozzolini A, Rapezzi C, Villani GQ (2012) Dronedarone: an innovating drug or a second-hand choice? How to find the way among guidelines, regulatory decisions and common clinical practice. G Ital Cardiol (Rome) 13:326-333
12. De Ponti F, Mugelli A (2012) Between guidelines and regulatory decisions: dronedarone's Odyssey. G Ital Cardiol (Rome) 13:334-336
13. Bergman U, Andersen M, Vaccheri A, Bjerrum L, Wettermark B, Montanaro N (2000) Deviations from evidence-based prescribing of nonsteroidal anti-inflammatory drugs in three European regions. Eur J Clin Pharmacol 56:269-272
14. Magrini N, Einarson T, Vaccheri A, McManus P, Montanaro N, Bergman U (1997) Use of lipid-lowering drugs from 1990 to 1994: an international comparison among Australia, Finland, Italy (Emilia Romagna Region), Norway and Sweden. Eur J Clin Pharmacol 53:185-189
15. WHO Collaborating Centre for Drug Statistics Methodology (2012) World Health Organization (WHO). Guidelines for ATC classification and DDD assignment. www.whocc.no. Accessed 20 March 2012
16. Wettermark B, Vlahovic-Palcevski V, Salvesen Blix H, Rønning M, Vander Stichele R (2008) Drug Utilization Research.159-195
17. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D (2002) Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 27:299-309
18. Chauhan D, Mason A (2008) Factors affecting the uptake of new medicines in secondary care - a literature review. J Clin Pharm Ther 33:339-348
19. Friberg L, Benson L, Rosenqvist M, Lip GY (2012) Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ 344:e3522. doi: 10.1136/bmj.e3522.:e3522-
20. Hansen ML, Gadsboll N, Gislason GH, Abildstrom SZ, Schramm TK, Folke F, Friberg J, Sorensen R, Rasmussen S, Poulsen HE, Kober L, Madsen M, Torp-Pedersen C (2008) Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers. Europace 10:395-402
21. Andrade JG, Connolly SJ, Dorian P, Green M, Humphries KH, Klein GJ, Sheldon R, Talajic M, Kerr CR (2010) Antiarrhythmic use from 1991 to 2007: insights from the Canadian Registry of Atrial Fibrillation (CARAF I and II). Hear Rhythm 7:1171-1177
22. Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF (2009) Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol 54:1089-1095